Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofloxacin + cyclophosphamide + docetaxel + doxorubicin + pegfilgrastim
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of three chemotherapy agents (cyclophosphamide, docetaxel, and doxorubicin), an antibiotic (ciprofloxacin), and a granulocyte colony-stimulating factor (pegfilgrastim). This regimen combines cytotoxic chemotherapy with ciprofloxacin, which may have both antimicrobial and potential anticancer properties, and pegfilgrastim for neutropenia management. Ciprofloxacin has demonstrated anticancer effects by decreasing proliferation and inducing apoptosis in cancer cells. Pegfilgrastim helps prevent infection by stimulating neutrophil production after myelosuppressive chemotherapy.
02
Targets
DNADNA gyraseCSF3R (Granulocyte colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)Topo IV (Bacterial Topoisomerase IV)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on ciprofloxacin + cyclophosphamide + docetaxel + doxorubicin + pegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciprofloxacin + cyclophosphamide + docetaxel + doxorubicin + pegfilgrastim.